Piccoli Maria-Teresa, Gupta Shashi Kumar, Thum Thomas
Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany; Excellence Cluster REBIRTH, Hannover Medical School, Hannover, Germany.
Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany.
J Mol Cell Cardiol. 2015 Dec;89(Pt A):59-67. doi: 10.1016/j.yjmcc.2015.02.002. Epub 2015 Feb 7.
Cardiovascular diseases are currently the main cause of morbidity and mortality worldwide. Ischemic heart disease, in particular, is responsible for the majority of cardiac-related deaths. Given the negligible regenerative potential of the human myocardium, there is a strong need for therapeutic strategies aiming at enhancing cardiomyocyte survival and proliferation following injury or at inhibiting their death. MicroRNAs (miRNAs) are small non-coding RNA molecules regulating gene expression at a post-transcriptional level with important functions in cardiovascular physiology and disease. It has been demonstrated that miRNAs can influence the ability of cardiomyocytes to enter the cell cycle and/or escape from death pathways. Additionally, long non coding-RNAs could be involved in such pathways. This review summarizes recent evidences on noncoding RNAs regulating proliferation and death of cardiomyocytes representing a future therapeutic for the treatment of heart diseases. This article is part of a Special Issue entitled SI: Non-coding RNAs.
心血管疾病是目前全球发病和死亡的主要原因。特别是缺血性心脏病,占大多数与心脏相关的死亡病例。鉴于人类心肌的再生潜力微乎其微,迫切需要采取治疗策略,以提高损伤后心肌细胞的存活和增殖能力,或抑制其死亡。微小RNA(miRNA)是小的非编码RNA分子,在转录后水平调节基因表达,在心血管生理和疾病中具有重要功能。已经证明,miRNA可以影响心肌细胞进入细胞周期和/或逃避死亡途径的能力。此外,长链非编码RNA可能参与这些途径。本综述总结了关于非编码RNA调节心肌细胞增殖和死亡的最新证据,这些证据代表了未来治疗心脏病的方法。本文是名为“SI:非编码RNA”的特刊的一部分。